SIQ17

Cat. No.:	HY-149846
CAS No.:	2151881-74-0
Molecular Formula:	$C_{32}H_{27}NO_2S$
Molecular Weight:	489.63
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

SIQ17 is an EGFR inhibitor that inhibits its activity by occupying the ATP-binding site, with IC_{50} of 0.62 nM. SIQ17 shows more effective EGFR-TK inhibitory activity compared to the known inhibitor Erlotinib (HY-50896) (IC_{50} of ~20 nM). SIQ17 can be used for cancer research[1]

In Vitro

SIQ17 (10 μM, 72 hours) has a stronger inhibits on cell viability of A431 cells compare to A549 cells[1].
SIQ17 (0-100 μM, 24 hours) has thecytotoxic effects, with IC_{50}s of 32.98 μM and 19.17μM for A549 cells and A431 cells respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	A549, A431
Concentration:	10 μM
Incubation Time:	72 hours
Result:	Had a stronger inhibits on cell viability of A431 cells compare to A549 cells

Cell Cytotoxicity Assay[1]

Cell Line:	A549, A431, Vero cell lines
Concentration:	0-100 μM
Incubation Time:	24 hours
Result:	Had thecytotoxic effects, with IC_{50}s of 32.98μM and 19.17μM for A549 cells and A431 cells respectively.

REFERENCES

[1]. Hengphasatporn K,et.al. Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors. ACS Omega. 2023 May 23;8(22):19645-19655.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA